Nevro to Present at BofA Securities 2021 Virtual Health Care Conference

Rhea-AI Summary

On April 13, 2021, Nevro Corp. (NYSE: NVRO), a leader in innovative solutions for chronic pain treatment, announced that Keith Grossman, Chairman and CEO, will present at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 2:00 PM ET. A live webcast will be available on Nevro's website, alongside archived recordings for investors. Nevro is renowned for its Senza spinal cord stimulation systems, which utilize HF10 therapy to significantly reduce opioid dependency in patients.

REDWOOD CITY, Calif., April 13, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 2:00 pm Eastern Time / 11:00 am Pacific Time.

A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com. 

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247  |  julie.dewey@nevro.com  

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-present-at-bofa-securities-2021-virtual-health-care-conference-301267445.html

SOURCE Nevro Corp.

FAQ

What is Nevro presenting at the BofA Securities Conference on May 11, 2021?

Nevro Corp. will be presenting at the BofA Securities 2021 Virtual Health Care Conference, focusing on innovative solutions for chronic pain treatment.

When will Keith Grossman present for Nevro at the conference?

Keith Grossman, Nevro's CEO, will present on May 11, 2021, at 2:00 PM Eastern Time.

Where can I access the webcast of Nevro's presentation?

The live webcast and an archived recording will be available on Nevro's website in the Investors section.

What is the significance of Nevro's HF10 therapy?

HF10 therapy has shown to reduce or eliminate opioid use in over 65% of patients in clinical studies, making it a significant advancement in chronic pain management.

What products are associated with Nevro's HF10 therapy?

Nevro's proprietary HF10 therapy is delivered through the Senza, Senza II, and Senza Omnia spinal cord stimulation systems.